Evidence map›Paper›PMID 29164326›Full record

ArticleWorld journal of urology2018

Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomy.

Mark Thalgott, Martina Kron, Johannes M Brath, Donna P Ankerst, Ian M Thompson, Juergen E Gschwend, Kathleen Herkommer

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The mFrontiers in pharmacology · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.International journal of molecular sciences · 2021
    Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Mark ThalgottDepartment of Urology, Urologische Klinik und Poliklinik, der Technische Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany. mark.thalgott@tum.de.ORCID http://orcid.org/0000-0001-8046-8639
Martina KronInstitute of Biometrics, University of Ulm, Ulm, Germany.
Johannes M BrathDepartment of Urology, Urologische Klinik und Poliklinik, der Technische Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany.
Donna P AnkerstDepartments of Life Sciences and Mathematics of the Technical University Munich, Munich, Germany.
Ian M ThompsonDepartment of Urology, University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, San Antonio, USA.
Juergen E GschwendDepartment of Urology, Urologische Klinik und Poliklinik, der Technische Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany.
Kathleen HerkommerDepartment of Urology, Urologische Klinik und Poliklinik, der Technische Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675, Munich, Germany.
TUM Klinikum · DETechnical University of Munich · DEThe University of Texas Health Science Center at San Antonio · USUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to determine if family history (FH) of prostate cancer (PC) influenced cancer control after radical prostatectomy (RP).

methodsPatients were evaluated in a prospectively-collected PC family database: The focus was on hereditary prostate cancer (HPC) defined by Johns Hopkins criteria and sporadic prostate cancer (SPC), rigorously defined by absence of prostate cancer in ≥ 2 brothers aged ≥ 60 years. Additionally, patients with first-degree (FPC) and non-first-degree PC (non-FPC) were assessed. Endpoints were biochemical recurrence-free survival (BRFS) and prostate cancer-specific survival (CSS). Finally, clinico-pathological characteristics were compared and multiple proportional hazards regression was used to identify prognostic factors.

resultsIn total 11,654 patients were included (807 HPC, 2251 FPC, 8072 non-FPC and 524 SPC). Familial imposition (HPC/FPC) was associated with a younger age at diagnosis. Thus, HPC patients were diagnosed 2.9 years earlier than SPC patients with more locally advanced tumors (≥ pT3). With a median follow up of 6.2 years (range 0-31.5) BRFS was significantly different when stratified by FH. In pairwise analyses BRFS differed significantly for HPC compared to SPC (HR = 1.27). Consecutively FH was identified as prognostic factor for BRFS (p = 0.021) together with age, PSA, pathologic characteristics and adjuvant androgen deprivation. Analyses of CSS did not show a difference.

conclusionPatients with FH of PC are likely to be diagnosed earlier and present a higher proportion of locally advanced disease. In addition, men with FH are at higher risk of biochemical recurrence after surgery but reveal similar outcomes regarding prostate cancer-specific survival.

Indexed as

FamilyProstatectomyAdultAgedAge of OnsetDatabases, FactualDisease-Free SurvivalHumansKallikreinsMaleMedical History TakingMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPrognosisKallikreinsKLK3 protein, humanProstate-Specific AntigenFamily historyHereditary prostate cancerRadical prostatectomySporadic prostate cancer

Identifiers

PMID29164326
OpenAlexW2770441814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.